Published in Cell Biol Int on September 02, 2007
Retracted Role of senescence and mitotic catastrophe in cancer therapy. Cell Div (2010) 1.51
Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene (2013) 1.39
Endopolyploidy in irradiated p53-deficient tumour cell lines: persistence of cell division activity in giant cells expressing Aurora-B kinase. Cell Biol Int (2008) 1.22
Ionizing radiation-induced responses in human cells with differing TP53 status. Int J Mol Sci (2013) 1.04
An automated fluorescence videomicroscopy assay for the detection of mitotic catastrophe. Cell Death Dis (2010) 1.01
Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell Int (2013) 1.01
Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer. Front Oncol (2014) 1.00
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. BMC Cancer (2012) 0.97
Atypical cell populations associated with acquired resistance to cytostatics and cancer stem cell features: the role of mitochondria in nuclear encapsulation. DNA Cell Biol (2014) 0.89
CoCl2, a mimic of hypoxia, induces formation of polyploid giant cells with stem characteristics in colon cancer. PLoS One (2014) 0.87
Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell Cycle (2014) 0.84
Slug overexpression induces stemness and promotes hepatocellular carcinoma cell invasion and metastasis. Oncol Lett (2014) 0.80
Macroautophagy-aided elimination of chromatin: sorting of waste, sorting of fate? Autophagy (2012) 0.79
Polyploidy Formation in Doxorubicin-Treated Cancer Cells Can Favor Escape from Senescence. Neoplasia (2015) 0.78
Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis (2016) 0.76
Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer. Br J Cancer (2017) 0.75
The development of a malignant tumor is due to a desperate asexual self-cloning process in which cancer stem cells develop the ability to mimic the genetic program of germline cells. Intrinsically Disord Proteins (2014) 0.75
The "virgin birth", polyploidy, and the origin of cancer. Oncoscience (2014) 0.75
Somatic polyploidy is associated with the upregulation of c-MYC interacting genes and EMT-like signature. Oncotarget (2016) 0.75
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood (2004) 3.38
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A (2006) 3.06
Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol (2007) 2.99
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood (2010) 2.31
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood (2008) 2.22
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood (2011) 1.91
Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest (2009) 1.76
Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood (2013) 1.58
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol (2011) 1.44
CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res (2003) 1.40
Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica (2009) 1.38
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood (2011) 1.34
Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood (2010) 1.19
Retracted STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. J Cell Sci (2005) 1.17
Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J Immunol (2011) 1.16
Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem (2008) 1.15
CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol (2010) 1.12
Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood (2012) 1.09
Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. BMC Cancer (2006) 1.05
Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks. J Cell Sci (2003) 1.02
Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell Int (2013) 1.01
Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation. Cell Biol Int (2011) 1.00
Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res (2008) 0.95
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother (2013) 0.90
Transforming growth factor-β directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas. J Biol Chem (2012) 0.89
Regulating the genome surveillance system: miRNAs and the p53 super family. Apoptosis (2010) 0.89
DNA damage causes TP53-dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells. Cell Cycle (2012) 0.88
The role of meiotic cohesin REC8 in chromosome segregation in gamma irradiation-induced endopolyploid tumour cells. Exp Cell Res (2009) 0.87
Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98). Br J Haematol (2014) 0.86
Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res (2013) 0.85
Family friction as ΔNp73 antagonises p73 and p53. Int J Biochem Cell Biol (2011) 0.84
B cells--masters of the immunoverse. Int J Biochem Cell Biol (2010) 0.84
Functional analysis of HIV type 1 Nef reveals a role for PAK2 as a regulator of cell phenotype and function in the murine dendritic cell line, DC2.4. J Immunol (2005) 0.81
CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. Exp Hematol (2012) 0.80
Apparent modulation of CD20 by rituximab: an alternative explanation. Blood (2004) 0.80
Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B). Eur J Immunol (2012) 0.80
Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization. J Immunol (2013) 0.80
Macroautophagy-aided elimination of chromatin: sorting of waste, sorting of fate? Autophagy (2012) 0.79
Complement: help or hindrance? Blood (2009) 0.79
Tumor cell embryonality and the ploidy number 32n: is it a developmental checkpoint? Cell Cycle (2011) 0.77
The potential effect of statins on rituximab immunotherapy. PLoS Med (2008) 0.77
FcγRIIB as a key determinant of agonistic antibody efficacy. Curr Top Microbiol Immunol (2014) 0.77
Role of STAT1 in the breast. JAKSTAT (2012) 0.76
Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood (2003) 0.76
Correction: Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus. PLoS One (2016) 0.75
Development of immunomonitoring of antibody‑dependent cellular cytotoxicity against neuroblastoma cells using whole blood. Cancer Immunol Immunother (2014) 0.75
Rehabilitation or the death penalty: autoimmune B cells in the dock. Eur J Immunol (2015) 0.75